Shares in Sartorius Stedim Biotech are retreating towards the lower bound of a horizontal trading range. Investors could use the proximity of this support area to initiate new long positions. Investors have an opportunity to buy the stock and target the € 145.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 122.3 support.
Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 43% by 2021.
The group's high margin levels account for strong profits.
The company is in a robust financial situation considering its net cash and margin position.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The stock is in a well-established, long-term rising trend above the technical support level at 111.1 EUR
Based on current prices, the company has particularly high valuation levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 47.69 times its estimated earnings per share for the ongoing year.
The company is not the most generous with respect to shareholders' compensation.
Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.